A 2026 retrospective analysis examines clinical trajectories and MRI-based triage of molecular uterine leiomyoma subtypes.

The study was published in the American Journal of Obstetrics & Gynecology in September 2026.

What this evidence adds

The work points toward more personalized care, although molecular classification does not mean every patient needs advanced testing.

Source: American Journal of Obstetrics & Gynecology, September 2026.